HR Notices From October 8The latest staffing, leadership and boardroom news from Michigan's technology-focused companies, institutions nad groiups
Synthetic Biologics Developing Monoclonal Antibodies To Treat Acinetobacter InfectionsSynthetic Biologics Inc., a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, today announced that it has initiated efforts to develop a monoclonal antibody (mAb) therapy for the treatment of acinetobacter infections.
Synthetic Biologics Reports First Quarter 2012 Financial ResultsSynthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, and summarized operational highlights.
HR Notices From May 14
HR Notices From May 11-13The latest personnel, leadership and boardroom news from Michigan's technology-focused companies, institutions and groups.
Synthetic Biologics Launches Free Investor Relations Mobile ApplicationSynthetic Biologics Inc. (NYSE Amex: SYN) Thursday announced the release of its investor relations mobile iPhone App, called the "SYN IR" App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
HR Notices From April 16The latest staffing, leadership and boardroom news from Michigan's technology-focused companies, institutions and groups.
Synthetic Biologics Announces Completion Of Enrollment In Trial Of MS DrugSynthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.
Adeona Becomes Synthetic Biologics, Inc.Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had received shareholder approval to change its corporate name to Synthetic Biologics Inc.